IL6 and breast cancer: The blockade of IL-6 would serve to block the downstream, protumourigenic effects of TAMs, thus supporting the idea that targeting of IL-6R and gp130 may present a better approach to inhibition of this pathway in breast cancers instead of the use of JAK/STAT3 inhibitors.